Anheuser-Busch InBev heads into its Q1 2026 results on May 5 having quietly staged one of the consumer-staples sector's better recoveries — and the data heading into the print shows more debate than conviction on either side.
The stock's 9% climb over the past month frames the question clearly. BUD closed at $75.56 on May 1, up 4% on the week and 18% year-to-date, against a consensus mean price target of $87.89. That gap implies roughly 16% further upside if the Street is right — not a stretched multiple by any measure. The PE runs at 16.9x and EV/EBITDA at 9.4x, both drifting higher over the past month as the price has rallied, though still modest for a $147 billion global consumer giant with nearly $23 billion in estimated EBITDA. Options positioning is calm rather than alarmed: the put/call ratio nudged up to 0.72 on Friday from a run of readings in the mid-0.65s, but remains fractionally below its 20-day average of 0.74 and well south of the 52-week high of 0.83. There is no options market signal of defensive hedging into the number.
The analyst community arrived at similar optimism from different directions, though the most recent moves in the data predate this event. Evercore ISI lifted its target sharply — from $75 to $100 while maintaining Outperform — following BUD's February earnings, when the stock jumped 4%. Wells Fargo raised its Overweight target twice in quick succession around the same report, ending at $88. The constructive pivot for bulls rests on volume trajectory: after years of US market-share pain, any evidence of stabilisation or sequential improvement in core markets would validate the re-rating story. Bears, by contrast, point to persistent headwinds — FX drag from emerging-market currencies, the $58 billion net debt load still demanding consistent deleveraging progress, and questions about whether premium-mix gains can offset volume softness in key markets. The EPS surprise factor score ranks in the 84th percentile, suggesting BUD has consistently exceeded expectations — a pattern the market will expect to continue.
The lending market tells a relaxed story, which matters when assessing how committed short sellers actually are. Short interest ticked up 11% over the past week to roughly 5.7 million shares, but the absolute level is small. Availability has loosened considerably from the April 28 extreme — when availability briefly tightened to its fullest point in over a year — back to a more comfortable reading, with cost to borrow running near 1.1%, a fraction of what a contested short position typically commands. The ORTEX short score of 48.9 sits squarely in neutral territory. Short sellers are present but hardly pressed. GQG Partners doubled its position to over 10 million shares in the most recent reporting period, while BlackRock added more than 4 million — flows that underline institutional interest on the buy side rather than a contested ownership structure.
The May 5 print will test whether the volume recovery narrative — the central pillar of BUD's re-rating case — has substance at the top-line level, and whether management's deleveraging commitment is showing up in net-debt progression fast enough to justify the multiple expansion already underway.
See the live data behind this article on ORTEX.
Open BUD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
